The complaint, filed by the firm SueWallSt, targets Phreesia’s disclosures between May 8, 2025, and March 30, 2026. According to the filing, the company projected 14% to 16% revenue growth for fiscal 2027 while allegedly ignoring clear signs that pharmaceutical manufacturers were reducing their spending. The lawsuit contends that management repeatedly assured investors of predictable visibility into these commitments, even as client demand weakened due to regulatory shifts and brand-specific pressures.
Phreesia Faces Class Action Over Alleged Revenue Projection Failures
A federal class action lawsuit has been filed against Phreesia, Inc., accusing the healthcare technology firm of misleading investors regarding the stability of its pharmaceutical marketing commitments. The litigation follows a sharp 27% decline in share price triggered by a significant reduction in the company's fiscal 2027 revenue guidance.
When the company finally adjusted its outlook on March 30, 2026, the projected revenue midpoint dropped by approximately $37 million, leading to a $3.03 per share loss for investors. Attorney Joseph E. Levi argues that the case highlights fundamental questions regarding disclosure obligations when companies build forward guidance on softening client contracts. Shareholders who purchased Phreesia securities during the specified period and suffered financial losses have until July 13, 2026, to apply for lead plaintiff status.
Comments (0)
No comments yet. Be the first!